This is a preview of subscription content, log in via an institution to check access.
Notes
Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation
The study was financed by Mundipharma.
Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation
Reference
Willis M, et al. Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. Diabetes Therapy : 2 Dec 2020. Available from: URL: https://doi.org/10.1007/s13300-020-00968-x
Rights and permissions
About this article
Cite this article
Canagliflozin in T2DM-related nephropathy improves QALYs, reduces cost. PharmacoEcon Outcomes News 868, 7 (2020). https://doi.org/10.1007/s40274-020-7339-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7339-7